About Us

Meet Celularity

Celularity is a clinical-stage cell therapeutics company investigating transformative allogeneic cellular therapies, engineered from the postpartum human placenta, in cancer immunotherapy and functional regeneration. Some of our placenta-derived allogeneic cell therapy products aim to augment immunity by harnessing a patient’s own immune system to combat disease.

Our other products seek to augment longevity by targeting organ and tissue repair and functional regeneration. With this approach, our ambition is to augment human immunity and longevity, and to improve human health.

Our vision is to be a world leading company accelerating commercial-scale cell therapeutics through our proprietary IMPACT™ platform, a transformative pillar in the treatment of cancer, inflammatory and age-related diseases.


Years of basic research

Into the biological activity of placental-derived cells

Pioneering technology platform

To harness the power of multiple placental-derived cell types

Significant unmet need globally

For inventory-ready, off-the-shelf allogeneic therapies

The time has arrived

For cellular medicine to be available for everyone

Meet Our Leadership Team

Backed by 100+ years of combined experience, our seasoned team of biopharmaceutical executives, scientists and clinicians have been integral to the success of numerous programs across discovery research, clinical development and commercialization in cancer immunotherapies and cell therapeutics.


Robert J. Hariri, M.D, Ph.D.

Founder & CEO

Dr. Hariri is a visionary trauma neurosurgeon, scientist, aviator, military medicine expert and entrepreneur. He has pioneered the use of stem cells to treat a range of life threatening diseases.


Xiaokui Zhang, PH.D.

EVP, Chief Scientific Officer


Nassir Habboubi, M.D.

Chief Medical Officer


John R. Haines

EVP, Chief Administrative Officer


Stephen A. Brigido DPM FACFAS

President, Functional Regeneration


David C. Beers

Chief Financial Officer


Beth Steinbrenner

EVP, Human Resources


Keary L. Dunn

EVP, General Counsel

Board of Directors


John Sculley

Vice Chair


Peter Diamandis, M.D.

Vice Chair


Andrew C. Von Eschenbach, M.D.

Board Member


Robin Smith M.D., M.B.A.

Board Member


Kok-Thay Lim

Board Member


Andrew Pecora, M.D., F.A.C.P., C.P.E.

Board Member


Henri Ji, PH.D.

Board Member


Jaisim Shah

Board Member